Sevindik, Ömür GökmenMergen, MahmutMergen, SenaMutlu, Yaşa GülBalık Aydın, BerrinSerin, İstemi2022-10-242022-10-242022Sevindik, Ö. G., Mergen, M., Mergen, S., Mutlu, Y. G., Balık Aydın, B. ve Serin, İ. (2022). To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission. Annals of Hematology, 101(11), 2545-2547. https://doi.org/10.1007/s00277-022-04938-01432-05840939-5555https://doi.org/10.1007/s00277-022-04938-0https://hdl.handle.net/20.500.12511/9872Dear Editor, Acute myeloid leukemia is the most common sub-type of acute leukemia in adulthood [1]. It has a detrimental prognosis with conventional combination chemotherapy, mainly with anthracyclines and cytarabine. Allogeneic stem cell transplantation has signifcantly prolonged the overall survival in a particular “eligible” patient population, but as AML is a disorder of the elderly, not all patients are able to proceed with allogeneic stem cell transplantation.eninfo:eu-repo/semantics/openAccessHypomethylating AgentLeukemia PatientFlt3-Positive Relapsed Acute MyeloidLetter101112545254710.1007/s00277-022-04938-0Q20008328381000012-s2.0-8513937813735906348Q1